Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia, approved for sale by the U.S. Food and Drug Administration (FDA) in 2014. The U.S. Drug Enforcement Administration (DEA) has scheduled this substance as controlled substance, as it may lead to physical or psychological dependence. This stable-labeled internal standard is suitable for use in quantitation of suvorexant levels by GC/MS or LC/MS for applications in clinical toxicology, therapeutic drug monitoring or urine drug testing.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.